Aripiprazole (Abilify) vs Aripiprazole lauroxil (Aristada Initio)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2/D3 and serotonin 5-HT1A receptor · full Schizophrenia pipeline
Aripiprazole (Abilify)
Marketed by Otsuka Holdings and partners
NCT00712686 · Phase 3 · completed
A randomised, double-blind, active-controlled trial of aripiprazole (n=355) against olanzapine (n=348) in acute schizophrenia, with two co-primary objectives. The published results are mixed: olanzapine was statistically superior on PANSS efficacy at week 6, so aripiprazole did not show non-inferiority, while aripiprazole caused significantly less weight gain at week 26. The registry has no posted results; the figures are from the publication (Fleischhacker et al., Biol Psychiatry 2009).
Next expected readout: July 2030 · NCT06969755 (registry estimate)
Reported efficacy
The mean change in the PANSS Total Score (from baseline to Week 6); The percentage of patients showing significant weight gain (a≥ 7% increase) (from baseline to Week 26): Mean change in PANSS Total Score from baseline to Week 6: aripiprazole -24.6 vs olanzapine -29.5 (random regression model); treatment difference 4.9 points, 95% CI 2.2-7.6, exceeding the pre-specified 6-point non-inferiority margin -- aripiprazole did not reach non-inferiority (olanzapine was statistically superior). Aripiprazole showed significantly less weight gain at Week 26: +0.13 kg vs +4.30 kg for olanzapine, and fewer patients with significant weight gain (21% vs 40%, p<.05). (mixed)
Result source: NCT00712686
Aripiprazole lauroxil (Aristada Initio)
Marketed by Alkermes plc
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Aripiprazole (Abilify) | Aripiprazole lauroxil (Aristada Initio) |
|---|---|---|
| PANSS total, change | -26.7 vs -21.2−5.5 vs placeboNCT0010206331 other results
| —Not reported |
| CGI-S, change | -1.2 vs -0.9−0.3 vs placeboNCT0010206332 other results
| —Not reported |
| PANSS response | —Not posted · NCT03485417 | —Not reported |
| PSP, change | —Not posted · NCT03485417 | —Not reported |
| Relapse (% of patients) | 19.4% vs 37.5%−18.1 vs placeboNCT011496551 other result
| —Not reported |
PANSS total, change
- Aripiprazole (Abilify)
- -26.7 vs -21.2−5.5 vs placeboNCT00102063
31 other results
- -28.6 vs -21.2 NCT00102063
- -19.4 vs -22.9 NCT02054702
- -1.3 vs 4.8 NCT01149655
- -1.2 vs 4.7 NCT01149655
- -1.0 vs 4.7 NCT01149655
- -1.0 vs 4.8 NCT01149655
- -1.0 vs 4.9 NCT01149655
- -1.1 vs 4.9 NCT01149655
- -0.9 vs 5.1 NCT01149655
- -0.8 vs 5.2 NCT01149655
- -0.6 vs 5.4 NCT01149655
- -1.1 vs 5.8 NCT01149655
- -1.0 vs 6.2 NCT01149655
- -1.0 vs 5.6 NCT01149655
- -0.8 vs 5.7 NCT01149655
- -0.9 vs 5.8 NCT01149655
- -0.4 vs 5.9 NCT01149655
- -0.3 vs 6.1 NCT01149655
- -0.6 vs 6.1 NCT01149655
- -0.7 vs 5.6 NCT01149655
- -0.8 vs 5.6 NCT01149655
- -0.2 vs 5.5 NCT01149655
- -0.2 vs 4.5 NCT01149655
- -1.2 vs 3.9 NCT01149655
- -1.6 vs 3.7 NCT01149655
- -1.2 vs 2.9 NCT01149655
- -0.6 vs 1.6 NCT01149655
- -0.4 vs 1.8 NCT01149655
- 0.1 vs -0.6 NCT01149655
- 0.2 vs -0.3 NCT01149655
- -7.7 vs -9.3 NCT00216476
- Aripiprazole lauroxil (Aristada Initio)
- —Not reported
CGI-S, change
- Aripiprazole (Abilify)
- -1.2 vs -0.9−0.3 vs placeboNCT00102063
32 other results
- -1.3 vs -0.9 NCT00102063
- 0.1 vs 0.3 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.0 vs 0.3 NCT01149655
- 0.0 vs 0.3 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.1 vs 0.4 NCT01149655
- 0.1 vs 0.4 NCT01149655
- 0.0 vs 0.3 NCT01149655
- 0.0 vs 0.3 NCT01149655
- 0.0 vs 0.3 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.0 vs 0.3 NCT01149655
- 0.0 vs 0.2 NCT01149655
- 0.0 vs 0.1 NCT01149655
- 0.0 vs 0.1 NCT01149655
- 0.0 vs 0.1 NCT01149655
- 0 vs 0.0 NCT01149655
- 0.0 vs 0.0 NCT01149655
- -0.8 vs -0.5 NCT01795547
- -0.1 vs -0.3 NCT00216476
- -1.3 vs -1.6 NCT02054702
- Aripiprazole lauroxil (Aristada Initio)
- —Not reported
PANSS response
- Aripiprazole (Abilify)
- —Not posted · NCT03485417
- Aripiprazole lauroxil (Aristada Initio)
- —Not reported
PSP, change
- Aripiprazole (Abilify)
- —Not posted · NCT03485417
- Aripiprazole lauroxil (Aristada Initio)
- —Not reported
Relapse (% of patients)
- Aripiprazole (Abilify)
- 19.4% vs 37.5%−18.1 vs placeboNCT01149655
1 other result
- 10% vs 39.6% NCT00705783
- Aripiprazole lauroxil (Aristada Initio)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Aripiprazole lauroxil (Aristada Initio): no structured comparison results are available for Schizophrenia.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Aripiprazole (Abilify): 4 of 4 rows · Aripiprazole lauroxil (Aristada Initio): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Aripiprazole (Abilify) |
|---|---|
| Dropout rate | 20%a NCT00345033 · Phase 4 · registry result, not featured evidence show 30 more results39.7% NCT01942148 · Phase 3 · registry result, not featured evidence 12.5% NCT01959035 · Phase 3 · registry result, not featured evidence 32.4% NCT01795547 · Phase 3 · registry result, not featured evidence 36.4% NCT02054702 · Phase 3 · registry result, not featured evidence — NCT01149655 · Phase 3 · registry result, not featured evidence — NCT01432444 · Phase 3 · registry result, not featured evidence 20.6%400/300 mg IM Depot NCT00731549 · Phase 3 · registry result, not featured evidence 40.2%10 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence 45%5 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence —5 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence —10 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence —300 or 400 mg NCT00706654 · Phase 3 · registry result, not featured evidence —25 or 50 mg NCT00706654 · Phase 3 · registry result, not featured evidence 84.7% NCT01001702 · Phase 3 · registry result, not featured evidence —Aripiprazole Depot NCT00705783 · Phase 3 · registry result, not featured evidence —Aripiprazole Depot - Depot Mainten NCT00705783 · Phase 3 · registry result, not featured evidence 37.8% NCT00216476 · Phase 3 · registry result, not featured evidence 26.8% NCT00102518 · Phase 3 · registry result, not featured evidence 16%10 mg/day NCT00102063 · Phase 3 · registry result, not featured evidence 17.6%30 mg/day NCT00102063 · Phase 3 · registry result, not featured evidence 14.6%24-30 mg/day NCT01942161 · Phase 2/3 · registry result, not featured evidence 20%6-12 mg/day NCT01942161 · Phase 2/3 · registry result, not featured evidence 22.9%2 mg/day NCT01942161 · Phase 2/3 · registry result, not featured evidence 11.1%400 mg NCT01646827 · Phase 1 · registry result, not featured evidence 26.3%400 mg NCT01646827 · Phase 1 · registry result, not featured evidence 6.7%400mg NCT01552772 · Phase 1 · registry result, not featured evidence 0%30 mg NCT00102479 · Phase 1 · registry result, not featured evidence 0%25 mg NCT00102479 · Phase 1 · registry result, not featured evidence 0%20 mg NCT00102479 · Phase 1 · registry result, not featured evidence 16.7% NCT01338298 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT00345033 · Phase 4 · registry result, not featured evidence show 30 more results5.9% NCT01942148 · Phase 3 · registry result, not featured evidence 5.7% NCT01959035 · Phase 3 · registry result, not featured evidence 10.8% NCT01795547 · Phase 3 · registry result, not featured evidence 3% NCT02054702 · Phase 3 · registry result, not featured evidence — NCT01149655 · Phase 3 · registry result, not featured evidence — NCT01432444 · Phase 3 · registry result, not featured evidence 2.9%400/300 mg IM Depot NCT00731549 · Phase 3 · registry result, not featured evidence 6.2%10 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence 0%5 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence —5 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence —10 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence —300 or 400 mg NCT00706654 · Phase 3 · registry result, not featured evidence —25 or 50 mg NCT00706654 · Phase 3 · registry result, not featured evidence 8.2% NCT01001702 · Phase 3 · registry result, not featured evidence —Aripiprazole Depot NCT00705783 · Phase 3 · registry result, not featured evidence —Aripiprazole Depot - Depot Mainten NCT00705783 · Phase 3 · registry result, not featured evidence 2.2% NCT00216476 · Phase 3 · registry result, not featured evidence — NCT00102518 · Phase 3 · registry result, not featured evidence 7%10 mg/day NCT00102063 · Phase 3 · registry result, not featured evidence 3.9%30 mg/day NCT00102063 · Phase 3 · registry result, not featured evidence 12.2%24-30 mg/day NCT01942161 · Phase 2/3 · registry result, not featured evidence 6.7%6-12 mg/day NCT01942161 · Phase 2/3 · registry result, not featured evidence 2.9%2 mg/day NCT01942161 · Phase 2/3 · registry result, not featured evidence —400 mg NCT01646827 · Phase 1 · registry result, not featured evidence —400 mg NCT01646827 · Phase 1 · registry result, not featured evidence 1.7%400mg NCT01552772 · Phase 1 · registry result, not featured evidence —30 mg NCT00102479 · Phase 1 · registry result, not featured evidence —25 mg NCT00102479 · Phase 1 · registry result, not featured evidence —20 mg NCT00102479 · Phase 1 · registry result, not featured evidence — NCT01338298 · Phase na · registry result, not featured evidence |
| Serious AEs | 0%a NCT00345033 · Phase 4 · registry result, not featured evidence show 30 more results10.3% NCT01942148 · Phase 3 · registry result, not featured evidence 3.4% NCT01959035 · Phase 3 · registry result, not featured evidence 8.3% NCT01795547 · Phase 3 · registry result, not featured evidence 3% NCT02054702 · Phase 3 · registry result, not featured evidence 3.1% NCT01149655 · Phase 3 · registry result, not featured evidence 14.2% NCT01432444 · Phase 3 · registry result, not featured evidence 8.8%400/300 mg IM Depot NCT00731549 · Phase 3 · registry result, not featured evidence —10 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence —5 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence 0%5 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence 13.4%10 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence 5.7%300 or 400 mg NCT00706654 · Phase 3 · registry result, not featured evidence 8.4%25 or 50 mg NCT00706654 · Phase 3 · registry result, not featured evidence 12.9% NCT01001702 · Phase 3 · registry result, not featured evidence —Aripiprazole Depot NCT00705783 · Phase 3 · registry result, not featured evidence 4.1%Aripiprazole Depot - Depot Mainten NCT00705783 · Phase 3 · registry result, not featured evidence 15.6% NCT00216476 · Phase 3 · registry result, not featured evidence 6.2% NCT00102518 · Phase 3 · registry result, not featured evidence 4%10 mg/day NCT00102063 · Phase 3 · registry result, not featured evidence 3.9%30 mg/day NCT00102063 · Phase 3 · registry result, not featured evidence 4.9%24-30 mg/day NCT01942161 · Phase 2/3 · registry result, not featured evidence 6.7%6-12 mg/day NCT01942161 · Phase 2/3 · registry result, not featured evidence 0%2 mg/day NCT01942161 · Phase 2/3 · registry result, not featured evidence 0%400 mg NCT01646827 · Phase 1 · registry result, not featured evidence 0%400 mg NCT01646827 · Phase 1 · registry result, not featured evidence 1.7%400mg NCT01552772 · Phase 1 · registry result, not featured evidence 0%30 mg NCT00102479 · Phase 1 · registry result, not featured evidence 0%25 mg NCT00102479 · Phase 1 · registry result, not featured evidence 0%20 mg NCT00102479 · Phase 1 · registry result, not featured evidence 0% NCT01338298 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | a eye irritation/swelling 6.3% (placebo 0%) psychiatric decompensation 6.3% (placebo 0%) psychiatric decompensation 6.3% (placebo 0%) NCT00345033 · Phase 4 · registry result, not featured evidence show 27 more resultsnasopharyngitis 45.6% somnolence 20.6% nausea 17.6% NCT01942148 · Phase 3 · registry result, not featured evidence weight increased 6.8% NCT01959035 · Phase 3 · registry result, not featured evidence accidental overdose 20.8% insomnia 11.8% weight increased 9% NCT01795547 · Phase 3 · registry result, not featured evidence akathisia 21.2% headache 12.1% constipation 9.1% NCT02054702 · Phase 3 · registry result, not featured evidence schizophrenia 9.2% (placebo 16.7%) weight increased 8.2% (placebo 10.4%) nasopharyngitis 7.1% (placebo 2.1%) NCT01149655 · Phase 3 · registry result, not featured evidence insomnia 6.7% akathisia 6.3% weight increased 2.3% NCT01432444 · Phase 3 · registry result, not featured evidence 400/300 mg IM Depot headache 7.6% nasopharyngitis 7% anxiety 6.8% NCT00731549 · Phase 3 · registry result, not featured evidence 5 - 30 mg QD pyrexia 35% headache 30% cough 15% NCT00239356 · Phase 3 · registry result, not featured evidence 10 - 30 mg QD back pain 7.2% anxiety 6.2% headache 6.2% NCT00239356 · Phase 3 · registry result, not featured evidence 300 or 400 mg insomnia 11.7% akathisia 10.6% headache 9.8% NCT00706654 · Phase 3 · registry result, not featured evidence 25 or 50 mg insomnia 13.7% back pain 11.5% weight decreased 9.2% NCT00706654 · Phase 3 · registry result, not featured evidence headache 15.3% influenza 10.6% weight increased 10.6% NCT01001702 · Phase 3 · registry result, not featured evidence insomnia 10% (placebo 9%) weight increased 9.7% (placebo 9.7%) anxiety 5.9% (placebo 7.5%) NCT00705783 · Phase 3 · registry result, not featured evidence insomnia 24.4% anxiety 15.6% headache 11.1% NCT00216476 · Phase 3 · registry result, not featured evidence extrapyramidal disorder 14.8% somnolence 12.9% headache 9.5% NCT00102518 · Phase 3 · registry result, not featured evidence 10 mg/day headache 16% (placebo 10%) extrapyramidal disorder 13% (placebo 5%) insomnia 11% (placebo 15%) NCT00102063 · Phase 3 · registry result, not featured evidence 30 mg/day extrapyramidal disorder 21.6% (placebo 5%) somnolence 21.6% (placebo 6%) tremor 11.8% (placebo 2%) NCT00102063 · Phase 3 · registry result, not featured evidence 24-30 mg/day nausea 22% insomnia 17.1% salivary hypersecretion 14.6% NCT01942161 · Phase 2/3 · registry result, not featured evidence 6-12 mg/day insomnia 20% somnolence 20% epistaxis 13.3% NCT01942161 · Phase 2/3 · registry result, not featured evidence 2 mg/day nausea 20% insomnia 14.3% nasopharyngitis 14.3% NCT01942161 · Phase 2/3 · registry result, not featured evidence 400 mg injection site pain 35.3% headache 23.5% akathisia 17.6% NCT01646827 · Phase 1 · registry result, not featured evidence 400 mg injection site pain 27.8% headache 22.2% akathisia 16.7% NCT01646827 · Phase 1 · registry result, not featured evidence 400mg injection site pain 6.7% toothache 6.7% blood creatine phosphokinase increased 5% NCT01552772 · Phase 1 · registry result, not featured evidence 30 mg headache 50% sedation 33.3% abdominal pain upper 16.7% NCT00102479 · Phase 1 · registry result, not featured evidence 25 mg abdominal pain upper 42.9% acne 28.6% dizziness 28.6% NCT00102479 · Phase 1 · registry result, not featured evidence 20 mg headache 50% insomnia 25% musculoskeletal stiffness 25% NCT00102479 · Phase 1 · registry result, not featured evidence nausea 50% (placebo 22.2%) vomiting 50% (placebo 38.9%) diarrhea 45% (placebo 38.9%) NCT01338298 · Phase na · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Aripiprazole (Abilify)
show 16 more results
show 37 more results
show 3 more results
show 1 more result
show 1 more result
+ 54 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aripiprazole (Abilify)'s landscape · Aripiprazole lauroxil (Aristada Initio)'s landscape